Switch to injectable cabotegravir–rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial

(2026) Switch to injectable cabotegravir–rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial. The Lancet. ISSN: 1474-547X

Abstract

Metadata

Item Type: Article
Copyright, Publisher and Additional Information:

© 2026 The Author(s)
Dates:
  • Published (online): 17 September 2026
Institution: The University of York
Academic Units: The University of York > Faculty of Social Sciences (York) > Centre for Health Economics (York)
Date Deposited: 18 Sep 2026 16:00
Last Modified: 04 Oct 2026 23:13
Published Version: https://doi.org/10.1016/S0140-6736(26)01537-0
Status: Published online
Refereed: Yes
Identification Number: 10.1016/S0140-6736(26)01537-0
Open Archives Initiative ID (OAI ID):

Download

Published Version

Filename: 1-s2.0-S0140673626015370-main.pdf

Description: Switch to injectable cabotegravir–rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial

Licence: CC-BY 2.5

CLICK TO DOWNLOAD [thumbnail of Switch to injectable cabotegravir–rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial]

Export

Statistics

View Altmetric information about this item.


CORE (COnnecting REpositories)